Clinical Trial Update: A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

View source ↗

Summary

A postmarketing safety study of JANUMET (sitagliptin phosphate/metformin hydrochloride) for type 2 diabetes was terminated and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Janumet (sitagliptin/metformin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Type 2 | Status: TERMINATED | Results posted: 2012-03-07